Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men

This study is being done to understand how testosterone, the major male sex hormone, controls the pituitary gland’s secretion of growth hormone (GH). GH is an important metabolic hormone, which controls sugar; fat and protein use in the body and maintains muscle strength and bone calcium content. Both testosterone and GH decline in older men. The age-related fall in these hormones probably contributes to relative frailty, reduced quality of life, bone loss, muscle wasting and impaired sexual function.

Official Title

Mechanisms of Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men: Modulation of GHRH, GHRP and Somatostatin Action by Estrogenic Versus Androgenic Steroids.

Conditions

•  Aging

Study Type

Interventional

Study Design

Randomised, Double-Blind, Placebo Control, Parallel Assignment.

Further Details

Primary Outcome Measures:

• How testosterone, controls the pituitary gland’s secretion of growth hormone (GH).

Repletion of testosterone in older men drives pulsatile GH secretion via conjoint facilitation of feedforward by the primary secretagogues GHRH and GHRP and repression of feedback by the dominant inhibitor, somatostatin; and, in corollary, testosterone acts via aromatisation to estradiol and/or reduction to 5 alpha-dihydrotestosterone.

Study Start

December 2005

Eligibility & Criteria

• Ages Eligible for Study: 50 Years to 80 Years
• Genders Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Healthy men between the ages of 50 and 80;
• Normal weight (within 30% of ideal body weight defined by New York Metropolitan Life tables); and
• Normal hematocrit (greater than 38%);
• Community dwelling; and
• Voluntarily consenting

Exclusion Criteria:

• Recent use of psychotropic or neuroactive drugs (within five biological half-live);
• Obesity (outside weight range above);
• Anemia (hematocrit < 38%);
• Drug or alcohol abuse, psychosis, depression, mania or severe anxiety;
• Acute or chronic organ-system disease;
• Endocrinopathy, other than primary thyroidal failure receiving replacement;
• Nightshift work or recent transmeridian travel (exceeding 3 time zones within 7 days of admission);
• Acute weight change (loss or gain of > 2 kg in 6 weeks);
• Allergy to administered compounds; and
• Unwillingness to provide written informed consent.

Total Enrolment

80

Contact Details

 

 Johannes D. Veldhuis, M.D.

 

 (507) 284-2511

Location:

Mayo Clinic
Rochester, Minnesota
United States, 55905